isatuximab
Sign in to saveAlso known as SAR-650984
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.
~15 min read
Encyclopedic overview
18 sectionsContents
- Medical uses
- History
- Structure and reactivity
- Reactions
- Available forms
- Mechanism of action
- Metabolism and toxicity
- Metabolism
- Toxicity
- Pregnancy
- Indications
- Efficacy and side effects
- Efficacy
- Side effects
- Effects on animals
- Names
- References
- External links
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.
The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis (inflammation of the airways in the lungs).
Excerpted from Wikipedia’s “isatuximab” article, available under the CC BY-SA 4.0 licence.